ALX Oncology Holdings (ALXO)
(Delayed Data from NSDQ)
$10.63 USD
-0.02 (-0.19%)
Updated May 31, 2024 04:00 PM ET
After-Market: $10.62 -0.01 (-0.09%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ALXO 10.63 -0.02(-0.19%)
Will ALXO be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ALXO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALXO
Novartis (NVS) Reports Positive Long-Term Data on CSU Drug
Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
ALXO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study
Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
Other News for ALXO
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
Buy Rating for ALX Oncology Amid Impressive Evorpacept and Padcev Combination Trial Results
Analysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (ALXO), Mirum Pharmaceuticals (MIRM) and IDEAYA Biosciences (IDYA)
Insider Sale: Chief Medical Officer of ALX Oncology Holdings Inc (ALXO) Sells Shares
ALX Oncology Holdings Inc (ALXO) Q1 2024 Earnings Analysis: A Detailed Look at Financials and ...